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Accepted 23 April 2020Introduction: Choriocarcinoma is a rare neoplasm (1/40000 pregnancies). In the context of a viable pregnancy,
the incidence is even lower (1/160000).
Case report: Awoman in her second pregnancy was admitted at 31 + 6weeks of gestation with hemoptysis and
abnormal vaginal bleeding. Numerous placental venous lakes, bilateral pulmonary nodules and a pleural effusion
were found. Pleural fluid β-HCG levels were elevated and a brain-chest-abdominal-pelvic CT scan led to the di-
agnosis of a high-risk gestational trophoblastic neoplasm. A caesarean section at 32 + 1 weeks of gestation was
performed. Six cycles of an EMA-CO chemotherapy regime were administered. β-HCG levels normalized after 3
cycles. Placental histopathology confirmed the presence of a gestational choriocarcinoma.
Conclusion: Choriocarcinoma is a highly aggressive tumor. In high-risk tumors, combination chemotherapy is the
first-line treatment, offering high remission rates. Treatment response is evaluated by monitoring blood β-HCG
levels, which should be long-term.







Gestational choriocarcinoma is a highly aggressive tumor with the
ability to produce early distant metastases [1]. Its incidence is estimated
to be about 1 in 40,000 pregnancies. In the context of a viable gestation,
the incidence is even lower (1 in 160,000 pregnancies) [2].
Several theories have been proposed to explain choriocarcinoma in
an ongoing viable pregnancy. Conversion of normal trophoblast cells
in the current gestation, transformation of residual trophoblast tissue
from a previous pregnancy or conversion of one of the products of con-
ception in a multiple pregnancy have been postulated [3].
Clinical presentation varies widely. Women may be asymptomatic
or can present with abnormal vaginal bleeding, hemoptysis, dyspnea,
headache, visual disturbances or jaundice. The last are suggestive of dis-
tant metastases. All cases are associated with significantly elevated β-
HCG (beta human chorionic gonadotropin)levels [4].
Due to its high chemosensitivity, the treatment of choriocarcinoma is
based on chemotherapy. The drug regime used is established according
to the stage and risk score of the disease at the time of diagnosis. It is cal-
culated fromacombinationof the International FederationofGynecology
andObstetrics (FIGO) staging systemand theWorldHealth Organizationlvarez-Sarrado).(WHO) prognostic scoring system. The first differentiates 4 stages based
on the extent of thedisease. The secondgives anumerical score that takes
into account the patient's and the tumor's characteristics [5].
Low-risk patients (FIGO stage I or stage II and III with a WHO risk
score below 7) are treated with a single-agent chemotherapy regime
(methotrexate or actinomycin-D) in order to maximize success rates
while minimizing toxicity [6]. In contrast, first-line treatment in high-
risk groups (FIGO stage IV or stage II and III with a WHO risk score
over 6) is a multi-agent chemotherapy regime because of the risk of re-
sistance to single-agent chemotherapy. The regime of choice is the com-
bination of etoposide,methotrexate, actinomycin-D, cyclophosphamide
and vincristine (EMA-CO) [7].
In low-risk groups, rates of complete remission after single-agent
chemotherapy reach 80%, and an overall survival rate of almost 100%
can be achieved by adding multi-agent therapy. Recurrence rates are
less than 5%.
In high-risk groups, around 85% of stage II and 75% of stage III pa-
tients reach full remission after primary multi-agent chemotherapy.
Overall cure rates reach 95–100% after secondary therapy. In stage IV
groups, up to 80% of patients are ultimately cured with intensive
multi-agent therapy and radiation or surgical adjuvant therapy when
needed. Recurrence rates are 8–10%, depending on the initial stage [8].
We present the case of a 22-year-old woman with a stage III high-
risk choriocarcinoma in the third trimester of pregnancywhopresented
with hemoptysis as her first symptom.
Fig. 2. Chest radiograph: bilateral pulmonary nodes of up to 20 mm suggestive of
metastases and bilateral pleural effusion.
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A 22-year-old woman in her so-far uncomplicated second preg-
nancywas admitted at 31+ 6weeks of gestationwith dyspnea and he-
moptysis that had developed in the past week. Her first pregnancy had
resulted in a spontaneous first-trimester abortion.
The hemoptysis was associated with coughing fits and pulse oxime-
try peripheral oxygen saturation was 95%. She also had painless vaginal
bleeding. A purplish friable nodular lesion of 1 cm in the backwall of the
vagina close to the introitus was found on pelvic examination. She was
hemodynamically stable and the CTG was normal. An abdominal ultra-
sound scan (Fig. 1) showed a posterior fundal placenta withmany large
venous lakes. Her bloodβ-HCG levelwas elevated at 267789.41mUI/ml,
while the level in the pleural fluid was 149,584mUI/ml. Chest radiogra-
phy (Fig. 2) showed various bilateral pulmonary nodes of up to 20 mm,
suggestive of metastases, as well as bilateral pleural effusions. A brain-
chest-abdominal-pelvic CT scan (Fig. 3) confirmed bilateral pulmonary
metastases and pleural effusions. It also showed a heterogeneous poste-
rior placenta with nodular growth.
Diagnosis of a high-risk stage III gestational trophoblastic neoplasm
wasmade. After fetal pulmonar maturationwith 2 doses of 12mg of in-
tramuscular betamethasone 24 h apart, an elective caesarean section a
t32+ 1weeks of gestation was performed. A 1400-gram girl was deliv-
ered, with Apgar scores of 9 after 1 min and 10 after 5 min, and venous
pH 7.40. The placenta was removed manually; the neoplasm measured
4 × 3 cm (Fig. 4).
The next day, chemotherapy treatment with EMA-CO was started,
which resulted in progressive improvement. The vaginal lesion disap-
peared after the first cycle of chemotherapy. Remission of the disease
(defined as 3 blood tests with undetectable β-HCG levels one week
apart) was achieved after 3 cycles of chemotherapy (51 days after the
start of treatment). Consolidation therapy comprised three additional
cycles.
Placental histopathology (Fig. 5) confirmed the presence of a gesta-
tional choriocarcinoma. One year after diagnosis, with continuing
monthly β-HCG monitoring, the patient remained in complete
remission.
3. Discussion
When diagnosing gestational trophoblastic neoplasia, differential di-
agnoses include invasive hydatidiform mole, choriocarcinoma,Fig. 1. Abdominal ultrasound: fund posterior placenta with many large venous lakes
shown with doppler colour.placental site trophoblastic tumor and epithelioid trophoblastic tumor.
In contrast to other tumors, gestational trophoblastic neoplasia is a clin-
ical diagnosis and no tissue for a definitive histopathologic confirmation
is needed prior to treatment. A persistent or abnormal elevation of β-
HCG levels along with the identification of clinical or radiological evi-
dence of distantmetastases support the diagnosis. Biopsies of distant le-
sions should not be performed because of the risk of hemorrhage due to
their significant vascularisation.
For this reason, pre-treatment evaluation is vital to ascertain the na-
ture of the tumor and assess stage and risk score of the disease to guide
the most appropriate treatment.
Invasive hydatidiform mole is the most frequent trophoblastic
tumor. It is characterized by an invasion of the myometrium together
with the presence of distant metastases. Diagnosis is confirmed by
imaging and β-HCG levels, and chemotherapy is the treatment of
choice. Placental site trophoblastic tumor and epithelioid trophoblastic
tumor represent less than 1% of all gestational trophoblastic tumors.
Blood β-HCG levels are low and they metastasise late. Surgery is the
first-line treatment, while chemotherapy is reserved for disseminated
disease [9].
Among all gestational trophoblastic tumors, choriocarcinoma is the
most aggressive histologic type, presenting the highest rate of metasta-
sis at the time of diagnosis, the most common being lung metastases
(80%), followed by vaginal (30%), brain (10%) and hepatic metastases
(10%) [10]. Because of its high vascularity, abnormal bleeding at those
locations could be the first clinical manifestation.
In our case, the patient presentedwith painless vaginal bleeding and
hemoptysis. The differential diagnosis of third-trimester vaginal bleed-
ing includes, apart from trophoblastic tumors, abruptio placentae, pla-
centa praevia, vasa previa and uterine rupture. She was
hemodynamically stable. No uterine activity or fetal heart rate abnor-
malities were present. Hemoptysis can be the first symptom in many
diseases, including lung cancer, infectious disease such as tuberculosis
or pulmonary thromboembolism. The X-ray image alongwith the pleu-
ral fluid cytology, culture and biochemical analysis allowed these pa-
thologies to be excluded in our patient.
After the presence of lung metastases, high β-HCG levels in pleural
fluid and a nodular growth in the placenta, a high-risk gestational
Fig. 3. Full-body CT scan: (1) bilateral pulmonary metastases and bilateral pleural effusion. (2) heterogeneous posterior placenta with mamelons and nodular growth.
Fig. 4. Placental node measuring 4 × 3 centimeters surrounded by necrotic tissue.
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with orwithout genital tract involvement) with a risk score of 10 points
in the WHO prognostic scoring system [11].
In high-risk patients, the combination regime that has shown the
best cure rate is EMA-CO (Etoposide, Methotrexate, Actinomycin D,
Cyclophosphamide and Vincristine) [12]. It is administered everyFig. 5. (1) H&E (Hematoxylin and eosin) ×10: choriocarcinoma showing malignant cytotropho
lactogen) ×20: malignant cytotrophoblast and syncytiotrophoblast cells positive for β-HCG bytwo weeks until β-HCG levels become undetectable for three con-
secutive weeks, at which point remission is considered to have
been achieved. Subsequently, at least three courses of EMA-CO
must be administered (known as consolidation therapy) [13]. In
our patient, remission was reached after 3 courses of chemotherapy,
and 3 additional courses were given to complete consolidation
therapy.
In high-grade gestational trophoblastic tumors, follow-up is under-
taken by monitoring blood β-HCG levels. Monthly determinations
over at least 18 months, and then semi-annually for 2 years and yearly
for up to 5 years are required [14].
The 5-year survival rate in high-risk stage III trophoblastic tumors
is high (up to 95%) [15]. After a year, our patient was continuing
with monthly β-HCG determinations, which had thus far proven
negative.
In conclusion, choriocarcinoma in a viable pregnancy is rare. Due to
its aggressiveness and capacity to produce distantmetastases, abnormal
bleeding from different organs in pregnant women alert the clinician to
this kind of pathology.
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